CA2403901A1 - 29 proteines humaines secretees - Google Patents

29 proteines humaines secretees Download PDF

Info

Publication number
CA2403901A1
CA2403901A1 CA002403901A CA2403901A CA2403901A1 CA 2403901 A1 CA2403901 A1 CA 2403901A1 CA 002403901 A CA002403901 A CA 002403901A CA 2403901 A CA2403901 A CA 2403901A CA 2403901 A1 CA2403901 A1 CA 2403901A1
Authority
CA
Canada
Prior art keywords
human
seq
polypeptide
sequence
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002403901A
Other languages
English (en)
Inventor
George Komatsoulis
Steven M. Ruben
Craig A. Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2403901A1 publication Critical patent/CA2403901A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

La présente invention concerne des nouvelles protéines humaines sécrétées ainsi que des acides nucléiques isolés contenant les régions de codage des gènes codant pour ces protéines. L'invention concerne également des vecteurs, des cellules hôtes, des anticorps et leurs méthodes recombinantes servant à produire ces protéines humaines sécrétées. Ladite invention se rapporte également à des méthodes diagnostiques et thérapeutiques utiles pour diagnostiquer et traiter des maladies, des troubles et/ou des états pathologiques associés à ces nouvelles protéines humaines sécrétées.
CA002403901A 2000-05-02 2001-04-26 29 proteines humaines secretees Abandoned CA2403901A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20119400P 2000-05-02 2000-05-02
US60/201,194 2000-05-02
US21214200P 2000-06-16 2000-06-16
US60/212,142 2000-06-16
PCT/US2001/013318 WO2001083510A1 (fr) 2000-05-02 2001-04-26 29 proteines humaines secretees

Publications (1)

Publication Number Publication Date
CA2403901A1 true CA2403901A1 (fr) 2001-11-08

Family

ID=26896490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002403901A Abandoned CA2403901A1 (fr) 2000-05-02 2001-04-26 29 proteines humaines secretees

Country Status (5)

Country Link
EP (1) EP1280815A1 (fr)
JP (1) JP2004527205A (fr)
AU (1) AU2001255668A1 (fr)
CA (1) CA2403901A1 (fr)
WO (1) WO2001083510A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2179742A1 (fr) * 2002-11-26 2010-04-28 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
US9845344B2 (en) * 2004-03-30 2017-12-19 Hoba Therapeutics Aps Therapeutic use of a growth factor, NsG33
ATE531383T1 (de) 2008-07-24 2011-11-15 Nsgene As Therapeutische verwendung eines wachstumsfaktors, metrnl
EP2621512B1 (fr) 2010-10-01 2016-04-06 NsGene A/S Utilisation de la météorine pour le traitement de l'allodynie, de l'hyperalgésie, de la douleur spontanée et de la douleur illusionnelle
CN104105501B (zh) 2011-09-05 2017-10-20 霍巴治疗公司 异常性疼痛、痛觉过敏、自发性疼痛、和幻痛的治疗

Also Published As

Publication number Publication date
AU2001255668A1 (en) 2001-11-12
JP2004527205A (ja) 2004-09-09
WO2001083510A1 (fr) 2001-11-08
EP1280815A1 (fr) 2003-02-05

Similar Documents

Publication Publication Date Title
CA2387959A1 (fr) 21 proteines humaines secretees
CA2388822A1 (fr) 27 proteines humaines secretees
CA2388777A1 (fr) 18 proteines secretees humaines
CA2385475A1 (fr) 18 proteines secretees humaines
CA2387799A1 (fr) 19 proteines humaines secretees
CA2382185A1 (fr) 48 proteines secretees humaines
CA2398227A1 (fr) 17 proteines secretees humaines
CA2388922A1 (fr) 23 proteines humaines secretees
CA2400638A1 (fr) 7 proteines humaines ovariennes et proteines associees au cancer des ovaires
CA2386641A1 (fr) 32 proteines humaines secretees
US20060160126A1 (en) 90 human secreted proteins
CA2382148A1 (fr) 25 proteines secretees humaines
CA2403901A1 (fr) 29 proteines humaines secretees
CA2365522A1 (fr) 48 proteines secretees humaines
CA2418676A1 (fr) 21 proteines humaines secretees
CA2478313A1 (fr) 41 proteines secretees humaines
CA2385169A1 (fr) 43 proteines secretees humaines
CA2423559A1 (fr) Proteines secretees humaines 22
CA2387261A1 (fr) 25 proteines secretes par l'homme
CA2388914A1 (fr) 15 proteines humaines secretees
CA2389724A1 (fr) 28 proteines humaines secretees
CA2420192A1 (fr) 21 proteines humaines secretees
CA2387964A1 (fr) 22 proteines humaines secretees
CA2389326A1 (fr) 35 proteines humaines secretees
CA2388019A1 (fr) 24 proteines humaines secretees

Legal Events

Date Code Title Description
FZDE Dead